Third Harmonic Bio — Corporate Update (May 2024)
21 slides from Third Harmonic Bio's corporate update, May 15, 2024
Slide 1: Advancing the next wave of focused medicine for inflammatory diseases
Exhibit 99.2 On advancing the next wave of FOCUSED medicine for inflammatory diseases MAY 2024 ©2024 THIRD HARMONIC BIO
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. Any statements made in this presentation that are not statements of historical fact, inclu
Slide 3: Recent Highlights
Recent Highlights • THB335 U.S. IND cleared; Phase 1 SAD/MAD trial underway with results expected in 1H’25 • Appointed Chris Dinsmore, Ph.D., to Chief Scientific Officer, Dennis Dean, Ph.D., to Chief Non-Clinical Development Officer and promoted Jennifer Dittman to Chief Development Operations Offic
Slide 4: THRD: Focused on KIT to Treat Mast Cell-Mediated Inflammatory Diseases
THRD: Focused on KIT to Treat Mast Cell-Mediated Inflammatory Diseases LARGE ESTABLISHED KIT: A NOVEL, MARKETS WITH HIGH CLINICALLY VALIDATED “PIPELINE-IN-A-TARGET” CLINICAL CANDIDATE: UNMET NEED TARGET THB335 POTENTIAL Millions of patients living Clinical validation of KIT Highly selective, oral sm
Slide 5: High Disease Burden in Chronic Spontaneous Urticaria
High Disease Burden in Chronic Spontaneous Urticaria A severe, yet undertreated dermal inflammatory condition “Out there, it’s a horrible • Prevalence: More than 1.5 million patients or 0.5-1% 1 point prevalence; ~70-80% female, mean age ~46 years world for urticaria patients” • Disease impact: CSU
Slide 6: KIT is the Master Regulator of Mast Cell Function and Survival
KIT is the Master Regulator of Mast Cell Function and Survival Oral small molecule approach to KIT offers multiple potential therapeutic advantages SCF dimer KIT Cytokines KIT receptor Allergen • Targeting mast cell vs specific activating Dimerization pathways or downstream mediators IgE Other provi
Slide 7: Early Clinical Proof-Of-Concept Demonstrated With THB001
Early Clinical Proof-Of-Concept Demonstrated With THB001 Discontinued cold inducible urticaria study results 1 THB001 MEAN TEMPTEST AND SERUM TRYPTASE CLINICAL RESPONSES GENERATED AT LOWEST TempTest (°Celsius) Serum Tryptase (µg/L) 30 6 PLANNED DOSE 25 5 • Rapid tryptase reduction: -83% mean change
Slide 8: THB001 Showed Evidence of Reactive Metabolite Formation
THB001 Showed Evidence of Reactive Metabolite Formation Mechanistic studies provide potential basis for observed transaminitis 14 [ C] THB001 COVALENT PROTEIN ADDUCT FORMATION IN HUMAN LIVER MICROSOMES IS REDUCED IN THE PRESENCE OF GSH OR CYP INHIBITION p<0.05 THB001 140 120 Reactive metabolite 100
Slide 9: THB335: A Next-Generation, Potent, and Highly Selective Wild-Type KIT Inhibitor
THB335: A Next-Generation, Potent, and Highly Selective Wild-Type KIT Inhibitor U.S. IND cleared with Phase 1 trial underway • Low nanomolar KIT potency with excellent kinome selectivity in biochemical and cell-based assays • Peripherally restricted biodistribution • Structural and metabolic improve
Slide 10: THB335 In Vitro Pharmacology Overview
THB335 In Vitro Pharmacology Overview Potent, selective, reversible KIT kinase inhibitor DiscoverX KinomeSCAN @ 1μM BIOCHEMICAL CELLULAR Kinase K HTRF KIT Multiple D Target (nM) IC (nM) (nM) 50 1 2 Percent Control KIT 1.5 16.1 5.0 – 7.9 0% 3 2 CSF1R 33 56 >3000 – >10000 KIT 0.1% PDGFRα NT 2710 NT 0.
Slide 11: THB335 is Metabolically Distinct from THB001
THB335 is Metabolically Distinct from THB001 Next-generation structural modifications functionally block the site of reactive metabolite formation MASS SPEC EXTRACTION ION CHROMATOGRAMS • Diol formed via a reactive epoxide identified as major Human Liver Microsomes metabolite of THB001 – GSH adduct
Slide 12: Next-Gen is Phenotypically Distinct from THB001 in Human Hepatocyte Culture
Next-Gen is Phenotypically Distinct from THB001 in Human Hepatocyte Culture No evidence for induction of oxidative stress pathways with next-generation analog of THB335 BULK RNA SEQ ANALYSIS VS VEHICLE CONTROL AT DAY 21 1 5 Detoxification Signals Oxidative Stress (NRF2) 2 Xenobiotic Metabolism 3 Liv
Slide 13: THB335 Drives Dose-Dependent Mast Cell Depletion and Efficacy In Vivo
THB335 Drives Dose-Dependent Mast Cell Depletion and Efficacy In Vivo Rat passive cutaneous anaphylaxis (PCA) model supports PK/PD correlation across species and test systems RAT THB335 PCA DAY 27 CONCENTRATION (ng/mL) THB335 5 mg/kg 100000 PO: Days 1-27 25 mg/kg 100 mg/kg 10000 10xIC50 Anti-DNP ant
Slide 14: Nonclinical Findings of KIT Inhibition Are Well-Characterized Across Programs
Nonclinical Findings of KIT Inhibition Are Well-Characterized Across Programs Subchronic and chronic toxicology studies of THB001 completed at up to >10x clinical exposures • No evidence of pharmacologically relevant activity against other kinases • Demonstrated reversibility of all effects Reproduc
Slide 15: THB335 Phase 1 SAD/MAD in Healthy Participants
THB335 Phase 1 SAD/MAD in Healthy Participants U.S. IND cleared, and trial initiated with data expected in 1H’25 Study Design • Randomized, placebo-controlled, double-blind, single and 14-day multiple ascending dose design Key Objectives • Assess safety and tolerability • Characterize pharmacokineti
Slide 16: "Pipeline-in-a-Target" Potential with KIT Inhibition
“Pipeline-in-a-Target” Potential with KIT Inhibition • Robust Phase 2 CSU study to support planned direct advancement to Phase 3 registrational studies • In parallel with CSU, planning to initiate Phase 2 studies in additional mast-cell mediated inflammatory disorders – Meaningful opportunity in sev
Slide 17: Third Harmonic Bio Next Steps
Third Harmonic Bio Next Steps Advancing THB335 into the clinic with a longer-term view toward franchise expansion • THB335 U.S. IND cleared; Phase 1 SAD/MAD trial underway with results expected in 1H’25 • Planning rapid advancement to robust Phase 2 study in CSU to support accelerated path to regist
Slide 18: Previously Presented Data
Previously Presented Data APPENDIX 18
Slide 19: First-Generation THB001 Phase 1b CINDU Study Overview
1 First-Generation THB001 Phase 1b CINDU Study Overview Discontinued dose escalation study designed to interrogate potential for therapeutic index optimization DESIGN AND OBJECTIVES STUDY SCHEMATIC • 3 doses (1:1:1) of THB001 (total N=30) for 12 weeks • Pharmacokinetics and serum tryptase levels THB
Slide 20: THB001 Phase 1b CINDU Study Efficacy Summary
Serum Tryptase µg/L First-Generation THB001 Phase 1b CINDU Study Efficacy Summary 4 of 5 subjects reached partial (n=2) or complete (n=2) responses at lowest planned dose of 200mg BID SUBJECT 1 >> SUBJECT 2>> SUBJECT 3>> SUBJECT 4 >> SUBJECT 5 >> PARTIAL RESPONSE PARTIAL RESPONSE NO RESPONSE COMPLET
Slide 21: THB001 Phase 1b CINDU Study Safety Summary
First-Generation THB001 Phase 1b CINDU Study Safety Summary THB001 HEMATOLOGY Hemoglobin and neutrophil count by subject over time Hemoglobin (g/dL) 16 • No serious or severe AEs Baseline 15 • Two moderate AEs of transaminitis which resolved 14 13 at weeks 17 and 25 of follow-up 12 • All other AEs w